Karyopharm Therapeutics (KPTI) Receives News Sentiment Rating of 0.14
Headlines about Karyopharm Therapeutics (NASDAQ:KPTI) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Karyopharm Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.7795429238155 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Karyopharm Therapeutics (KPTI) Expected to Announce Earnings of -$0.67 Per Share (americanbankingnews.com)
- 2 Small Biotechs To Buy This Week (seekingalpha.com)
- BidaskClub Lowers Karyopharm Therapeutics (KPTI) to Strong Sell (americanbankingnews.com)
- Karyopharm Therapeutics Inc. (KPTI) stock price is showing notable positive signal for long-term investors on basis of … (analystrecommendation.com)
- Selinexor Gains FDA Fast Track Designation for Refractory Multiple Myeloma Patients (myelomaresearchnews.com)
Several equities analysts have recently issued reports on KPTI shares. BidaskClub raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. HC Wainwright upped their target price on Karyopharm Therapeutics to $26.00 and gave the company a “buy” rating in a report on Thursday, March 15th. Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the company a “buy” rating in a report on Wednesday, March 21st. JPMorgan Chase upped their target price on Karyopharm Therapeutics from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Tuesday, April 10th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and issued a $22.00 target price on shares of Karyopharm Therapeutics in a report on Friday, March 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $20.20.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Thursday, March 15th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.14). The business had revenue of $1.53 million during the quarter, compared to analyst estimates of $2.26 million. During the same period last year, the business posted ($0.65) earnings per share. The company’s revenue for the quarter was up 3163.8% compared to the same quarter last year. equities research analysts predict that Karyopharm Therapeutics will post -2.82 EPS for the current year.
In other Karyopharm Therapeutics news, CEO Michael Kauffman sold 10,000 shares of the stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $10.09, for a total transaction of $100,900.00. Following the completion of the transaction, the chief executive officer now directly owns 522,143 shares of the company’s stock, valued at $5,268,422.87. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mansoor Raza Mirza sold 2,500 shares of the stock in a transaction on Monday, March 12th. The shares were sold at an average price of $17.01, for a total value of $42,525.00. Following the transaction, the director now directly owns 2,500 shares of the company’s stock, valued at $42,525. The disclosure for this sale can be found here. Over the last three months, insiders have sold 69,000 shares of company stock valued at $952,625. 14.71% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Karyopharm Therapeutics (KPTI) Receives News Sentiment Rating of 0.14” was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2018/04/17/karyopharm-therapeutics-kpti-receives-news-sentiment-rating-of-0-14.html.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.